Evotec AG (NASDAQ:EVTCY) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS
Evotec AG (NASDAQ:EVTCY) released its quarterly earnings data on Thursday. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.07 by $0.03, Morningstar.com reports. The company had revenue of $58.52 million during the quarter, compared to analysts’ expectations of $50.06 million.
Evotec AG (EVTCY) traded up 2.38% during trading on Friday, reaching $33.50. The company’s stock had a trading volume of 1,898 shares. Evotec AG has a 1-year low of $9.65 and a 1-year high of $34.32. The stock has a market capitalization of $2.34 billion and a PE ratio of 56.02. The stock has a 50 day moving average price of $30.47 and a 200 day moving average price of $23.66.
EVTCY has been the topic of several analyst reports. DZ Bank AG reiterated a “sell” rating on shares of Evotec AG in a research note on Monday, July 31st. Deutsche Bank AG reiterated a “neutral” rating on shares of Evotec AG in a research note on Wednesday, May 3rd. Finally, Berenberg Bank lowered Evotec AG from a “buy” rating to a “hold” rating in a research note on Tuesday, June 6th.
Evotec AG Company Profile
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners’ target through a range of commercial structures, including research fees, milestones and/or royalties.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with Analyst Ratings Network's FREE daily email newsletter.